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Institute of Complementary Medicine, University of Bern, Bern, Switzerland
An increasing cancer incidence affecting any age and social class is putting serious
strain on populations and health care systems around the world. This systematic
literature search aims (i) to examine the correlation of heart rate variability (HRV) and
cancer patients’ prognosis, (ii) to examine the relationship of HRV and clinicopathological
features, and (iii) to compare HRV between different patient groups, and between patient
and control groups. We conducted a systematic literature review following the PRISMA
Statement. We searched the PubMed and EMBASE databases for publications released
by December 2017. The search terms were: “cancer” AND “heart rate variability” AND
“human” NOT “animal” NOT “review.” A total of 19 studies were finally included in this
review. Most publications were high-quality observational studies. The studies showed
that higher HRV correlated positively with patients’ progression of disease and outcome.
Thus, we conclude that individuals with higher HRV and advanced coping mechanisms
seem to have a better prognosis in cancer progression. HRV appears to be a useful
aspect to access the general health status of cancer patients.
Keywords: HRV, tumor, vagal nerve, malignancy, prognosis
INTRODUCTION
With approximately 8.8 million cancer-related deaths and 14 million new cancer cases per year,
at present neoplastic diseases are a significant cause of morbidity and mortality worldwide. The
number of new cases of cancer is expected to rise by about 70% over the next two decades (Stewart
et al., 2014) as key risk factors increase, including exposure to physical (e.g., ionizing and non-
ionizing radiation) and chemical carcinogens (e.g., acrylamide, aflatoxin, endocrine disruptors),
lifestyle choices (e.g., tobacco use, alcohol use, unhealthy diet, physical inactivity and circadian
disruption) and infections (e.g., human papillomavirus, hepatitis B-virus, helicobacter pylori).
Clinical research spans many different fields with the aim of improving diagnosis, treatment,
and prognosis through increased knowledge about cancer pathophysiology. Although guidelines
support cancer care, the management of cancer patients requires predictions and decisions on an
individualized rather than generalized basis, taking into account the patient’s clinicopathological
and psychological situation. Hence, data on prognostic factors are integral to improve patients’
specific prognosis (Gidron et al., 2014). Prognostic factors such as tumor stage and tumor markers
[e.g., prostate-specific antigen (PSA), alpha-fetoprotein (AFP), human chorionic gonadotropin
(hCG)] have been shown to correlate with the course of disease and/or prognosis (Mead and
Stenning, 1997; Gospodarowicz and O’Sullivan, 2003). Currently, there is much interest around
such prognostic factors but their reliability remains a subject of debate. Additionally, there are
many other host-related or environmental factors (e.g., pollution, nutrition) which may affect the
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outcome. Host-related factors include general variables such as
age, sex and ethnicity, inflammatory markers (e.g., C-reactive
protein) and organ functioning (forced expiratory volume in one
second in lung cancer), as well as immune status and personal
coping mechanisms (Moreno-Smith et al., 2010). These, together
with potentially undiscovered factors, may have an impact on
disease control.
Heart rate variability (HRV) is a biomarker of the autonomic
nervous system (ANS) function and provides a measure of
ANS through sympathetic and parasympathetic modulation of
cardiac function (Karvinen et al., 2013). The vagal nerve is
the main component of the parasympathetic system and the
main modulator of the parasympathetic innervation of the heart.
HRV analysis has already been used in recreational sports,
sports medicine and other clinical fields to monitor the level of
physical fitness and biofeedback procedures (Park and Thayer,
2014; Prinsloo et al., 2014; Dong, 2016; Penzel et al., 2016).
HRV analysis has the potential to provide additional valuable
insights into multiple physiological and pathological conditions
(Malik et al., 1996). It further serves as a potential marker
of stress and health in functions of an organism associated
with adaptability and health (Thayer et al., 2012). In a recent
review by Arab et al. (2016), chemotherapy or surgery was
shown to have an important effect on HRV, which indicated
an impairment of the patients’ autonomic function, i.e., an
autonomic dysfunction. In another recent review that also
included a meta-analysis, the overall survival of cancer patients
was found to be significantly longer in a group with higher
HRV compared to a group with lower HRV (Zhou et al.,
2016).
The aim of this systematic literature search was to provide
and appraise an overview of publications which report on the
following three research questions: (i) What is the role of HRV
as a biomarker and prognostic factor in cancer disease? (ii) How
is HRV correlated with cancer progression? and (iii) What is
the value of HRV in predicting cancer patients’ prognosis and
survival outcome in comparison to different patient groups, or
healthy individuals? The search focused on adult cancer patients
with any kind of cancer disease whose HRV was measured during
a follow-up period.
MATERIALS AND METHODS
A systematic review was conducted according to the PRISMA
Statement (Moher et al., 2009). The literature search was
performed on the databases PubMed and EMBASE. The search
included all publications until December 2017 and was conducted
independently by two of the authors (KB and EK). Only studies
on humans were included. The search terms were: “cancer”
AND “heart rate variability” AND “human” NOT “animal” NOT
“review.”
The process of the literature search is depicted in Figure 1A.
Data Collection
Publications were included when meeting the following criteria:
study participants were adult cancer patients with any kind of
cancer. Any number of participants and any year of publication
were accepted. The prognostic factor HRV had to be assessed at
least once and set in relation to other variables (e.g., progression-
free survival or survival time), to prognosis or compared to
healthy individuals. Meta-analysis and letters, poster abstracts or
unpublished manuscripts were excluded. However, the reference
lists of reviews were screened for additional publications of
relevance for this systematic review.
The aim of the included studies had to be at least one of
the following: (i) Investigating the correlation between HRV and
patients’ prognosis, (ii) Examining the relationship of HRV with
clinicopathological features, or (iii) Comparing HRV in different
patient groups, or between patient and control groups.
While screening titles and abstracts, duplicates were removed.
Studies were instantly excluded if they were not related to
cancer patients, if the test species were not human and if the
language of the publication was not English, French, or German.
Publications with abstracts not related to the topic or not meeting
the inclusion criteria were excluded. The full texts were read,
and data extracted and appraised by two researchers (KB and
EK) independently. Publications had to be available either via
journals or on other scientific platforms which provided access
to the Swiss University libraries. Authors were contacted if
publications were not accessible through these routes. If there
was no response within the period the literature search was
conducted, the respective publications were excluded.
Extracted data were sorted and categorized according to the
patient characteristics, HRV variables, and outcome variables.
The main results are listed in Table 1.
Classification of bias and a Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) scoring
evaluation were performed in accordance with the Cochrane
guidelines (Higgins and Altman, 2008).
RESULTS
A total of 588 matches were screened. Following the inclusion
and exclusion criteria described above, 19 studies were finally
included in this systematic review. Of these 19 studies, 6 were
retrospective studies and 13 prospective studies. The number of
patients per study varied between 30 and 657 (mean: 154.68,
median: 68 patients). HRV in each patient was described, but
different indices in time or frequency domain were determined
in the different studies. Table 1 provides a description of the
publications included in this systematic review. Figures 1B–M
visualizes the key findings of the studies reviewed.
The studies included in this systematic review were performed
in patients with various types of cancer, i.e., breast cancer (BC):
with a total of 196 patients; prostate cancer (PrC): 113; colorectal
cancer (CRC): 208; non-small cell lung cancer (NSCLC):
133; stomach and esophagus cancer: 28; bladder cancer: 3;
lung cancer: 51; pancreatic cancer: 332; hepatocellular- and
hepatobiliary cancer: 43; genitourinary cancer: 22; gynecologic
cancers (uterus, cervix, ovary): 125; head and neck cancer: 127;
brain metastasis: 40; primary brain tumor: 33; leukemia non-
acute: 14, acute: 22; metastatic carcinoid tumor: 35; liver cancer:
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TABLE 1 | Summary of the 19 selected publications.
Study Patient characteristics Controls HRV variables Outcome
variables
Main results
Study topic: HRV influence on prognosis
Guo et al.,
2015
n = 651
Group 1, n = 520,
SDNN ≥ 70 ms
Group 2, n = 131,
SDNN < 70 ms
None 20- to 24-h ECG
monitoring (SDNN,
SDANN, rMSSD, pNN50)
Survival - Patients in group 2 had a significantly
lower survival rate than patients in
group 1 (25% of patients in group 2
died within 18.7 weeks vs. 78.8 weeks
in group 1 patients, p < 0.0001)
Couck et al.,
2016
n = 272
52.8% locally advanced
pancreatic cancer; 47.2%
metastatic cancer Mean age:
60.0 (±11.5) years
None 10 s ECG for HRV (time
domain: SDNN, rMSSD),
archival electronic records
taken near diagnosis
Cut-off: 20 ms (SDNN)
- High HRV > 20 ms
- Low HRV < 20 ms
Survival - SDNN significantly correlated with
survival, independent of all
confounders. Patients with low SDNN
survived on average only 64.05 days
versus those with high SDNN who
survived 133.52 days
Giese-Davis
et al., 2015
n = 87
One group with MRBC Mean
age: 54.2 ± 9.92 years,
females only
None 5 min ECG for HRV (time
domain: HR, frequency
domain: HF)
Survival - Higher baseline HF with significantly
longer survival - Visceral metastasis
status and baseline heart rate related to
HF - Combined HF and HR improved
survival prediction
Wang et al.,
2013
n = 40
One group with BM from 24
NSCLC, 6 SCLC, 4 BC, 6
others: median age: 61 (39–75)
years, 21 females, 19 males;
patients with no previous brain
OP or RT
None 5 min ECG for HRV (time
domain: SDNN, rMSSD),
taken before WBRT,
SDNN < 10 ms or ≥ 10 ms
and rMSSD < 7 ms
or ≥ 7 ms used as
prognostic factors in
survival analysis
Overall survival
(OS)
- SDNN < 10 ms as significant
independent prognosticator for OS
Chiang et al.,
2013
n = 138
One group including LC, CRC,
SC, hnC, PaC, GuC, EC,
others; mean age: 67.6 ± 12.2
years, 62 females, 76 males
None 5 min ECG for HRV
(frequency domain: HF, TP,
LF/HF), data is logarithm
transformed
Survival status
after 7 days
- Association between InHPF and 7-day
survival in patients with non-lung cancer
Chiang et al.,
2010
n = 33 One group with terminal
HCC; mean age: 66.2 ± 13.8
years, 9 females, 24 males
None 5 min ECG for HRV
(frequency domain: HF, TP)
Time to death
(TTD)
- HF power significantly associated with
longer TTD
- Higher TP significantly associated with
longer TTD
- 67% accuracy of 1-week-TTD
prediction for HRV and TP
-73% accuracy of 2-week TTD prediction
for HF, 82% for TP
Fadul et al.,
2010
n = 47
One group with LC, GITC;
median age: 59 (20–79) years,
males only
None 20 min ECG for HRV (time
domain: SDNN, frequency
domain: VLF, LF, HF)
Survival (interval
between study
entry and date
of death)
- Statistically significant association
between survival duration in days and
presence of autonomic nervous system
dysfunction (i.e., ET > 2)
- Trend toward significant association
between survival and lower SDNN
- Strong correlation between ET and
SDNN, VLF
- No significant association between
frequency domain parameters and
survival
Kim et al., 2010 n = 68
One group with LC, SC, EC,
hbC, GC, CRC; age: 26–84
years, 34 females, 34 males
None 5 min ECG for HRV (time
domain: HR, SDNN,
rMSSD, frequency domain:
TP, LFP, HFP)
Survival
(duration, from
testing until
date of death)
- SDNN of 21.3 ms or less significantly
associated with longer survival duration
- HR greater than 100 bpm significantly
associated with longer survival duration
Hoffmann et al.,
2001
n = 35
One group with metastatic
carcinoid tumor (carcinoid
syndrome); mean age:
56 ± 11 years, 14 females, 21
males
None 24-h ECG for HRV (time
domain: SDNN, rMSSD,
pNN50)
Survival
duration with
follow-up of
18 ± 7 months
- Low SDNN combined with CHD with
significantly higher mortality
(Continued)
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TABLE 1 | Continued
Study Patient characteristics Controls HRV variables Outcome variables Main results
Study topic: HRV in relation to tumor burden
Gidron et al.,
2014
n = 185
Two groups:
72 with CRC, mean age:
63.7 ± 10.8 years, 45 females,
27 males
113 with PrC, mean age
65.1 ± 8.9 years, males only
None 10 s ECG for HRV (time
domain: SDNN), archival
electronic records taken
near diagnosis
Cut-off 20 ms (SDNN)
- High HRV > 20 ms
- Low HRV < 20 ms
Carcinoembryonic
antigen (CEA) for CRC
at 12 months
Prostate specific
antigen (PSA) for PrC at
6 months
Division of patients into cancer stage
1–4:
- Low HRV with significantly higher
CEA levels in stage 4 than in stage 1
- High HRV with no significant
difference between stage 4 and stage
1 CEA levels
- Significant increase of CEA levels in
patients with stage 4 and low HRV
after 12 months (non-significant for
CEA stage 1–3 and low HRV)
- Low HRV with significantly higher
PSA levels in stage 4 than in stage 2
- High HRV with insignificant difference
between stage 4 and stage 2 PSA
levels
- Significant increase of PSA levels in
patients with stage 4 and low HRV
after 6 months (insignificant for PrC
stage 2,3 and low HRV)
De Couck
et al., 2013
n = 244
Two groups:
113 with PrC, mean age:
65.06 ± 8.87 years, males only
133 with NSCLC, mean age:
62.2 ± 10.2 years (no gender
specification provided)
None 10 s ECG for HRV (time
domain: SDNN, rMDSS),
electronic records taken
near diagnosis
Cut-off 20 ms (SDNN)
- High HRV > 20 ms
- Low HRV < 20 ms
PrC: PSA levels at 6
months and 2 years
NSCLC: OS in full
sample and survival
time in deceased
patients
- HRV parameters significantly
predicted PSA levels at 6 months
independent of confounders
- HRV significantly predicted PSA levels
only in stage 4 (metastatic stage), not
in stage 2/3
- HRV parameters with no significant
correlation to OS or survival time
- Higher HRV in younger (under 65
years) NSCLC patients significantly
predicted longer survival time
- NSCLC patients have significantly
lower SDNN than PrC patients
Mouton et al.,
2012
n = 38
One group with CRC; mean
age: 63.7 ± 10.8 years, 24
females, 14 males
None 10 s ECG for HRV (time
domain: SDNN, rMDSS),
archival electronic records
taken near diagnosis
Cut-off 20 ms (SDNN)
- High HRV > 20 ms
- Low HRV < 20 ms
CEA levels at 12
months from diagnosis
Examination of
evolution of CEA at
diagnosis, 6 and 12
months later
- Baseline SDNN significantly, inversely
predicted CEA levels at 12 months,
independent of confounders
- Low HRV significantly predicted
higher CEA levels at 12 months
- rMSSD with no predictive significance
- HRV-CEA relationship significant in
patients with palliative treatment, not
curative treatment
Study topic: HRV comparison
Bijoor et al.,
2016
n = 184
Two groups with hnC, GITC,
GyC; median age : 54 (range
40–68)
Early stage Group: n = 59
Advanced stage Group:
n = 128
n = 150
Age and
gender
matched
healthy
individuals
1 min ECG for HRV (time
domain: rMSSD)
HRV (rMSSD) of
patients compared with
healthy subjects
HRV (rMSSD) of early
stage compared to
advanced stage group
- rMSSD significantly lower in cancer
group compared to healthy group
- rMSSD significantly lower in
advanced stage of cancer compared-
to early stage
Palma et al.,
2016
n = 30
Two groups with BC
BCG1: <18 months since
breast cancer surgery; mean
age 51.1 ± 8.6
BCG2: >18 months since
breast cancer surgery; mean
age 56.3 ± 7.4
n = 15
age matched
healthy women;
mean age
51.2 ± 10.8
30 min HR recording with
Polar S810i (time domain:
mean RR, rMSSD, SDNN,
frequency domain: LF, HF,
LF/HF)
HRV of breast cancer
survivors after surgery
compared to cancer
free women
Comparison of HRV of
patients according to
elapsed time since the
surgery
- rMSSD, SDNN and HF are
significantly reduced in post breast
cancer groups compared to
cancer-free group
- No difference in HRV parameters
regarding to the postoperative period
(Continued)
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TABLE 1 | Continued
Study Patient characteristics Controls HRV variables Outcome
variables
Main results
Koszewicz
et al., 2016
n = 33
One group with pBT; mean
age 53.0 ± 15.2
N = 43
Healthy volunteers, mean
age 51.7 ± 10.1
HRV in% at rest (LF, HF,
LF/HF)
HRV of patients
compared with
healthy volunteers
- HRV% significantly lower in
patients group- No significant
difference in LF, HF or LF/HF
De Couck and
Gidron, 2013
n = 657
One group with PrC, PaC,
CC, OC, NSCLC; mean age:
63.09 ± 11.07 years, 309
females, 348 males
One group
21’438 healthy adults for
HRV-control
10 s ECG for HRV (time
domain: SDNN, rMSSD),
archival electronic records
taken near diagnosis
Cut-off 20 ms (SDNN)
- High HRV > 20 ms
- Low HRV < 20 ms
HRV (indices) of
patients compared
with HRV of healthy
subjects
- Mean HRV of cancer patients
significantly lower than HRV of
healthy samples
- Significantly lower HRV in
advanced stages (3, 4) than early
stages
- Lower HRV in patients with
age > 65 years
- HRV with tendency to
significance in group < 65
- OC and NSCLC with significantly
lower HRV than other cancer
types
Lin and Chen,
2010
n = 124
Two groups with hnC, LC,
BC, GITC and others
Group with metastasis:
n = 61, mean age:
62.3 ± 12.7 years, 36
females, 25 males
Group without metastasis:
n = 63, mean age:
52.6 ± 10.7 years, 35
females, 28 males
None 5 min ECG for HRV (time
domain: HR, SDANN,
frequency domain: TP, LF,
HF, VLF, LF/HF ratio)
Comparison of
HRV of patients
with and without
metastasis
- HR significantly higher in patients
with metastasis - SDANN, TP, LF
and VLF significantly lower in
patients with metastasis
- No statistical significance of HF
and LF/HF ratio between the two
groups
Nevruz et al.,
2007
n = 36
1 group with n = 14 ALL,
n = 22 AML; mean age:
34 ± 16 years, 11 females,
25 males
No previous treatment
n = 32 age-matched
healthy subjects; 9 female,
23 males, mean age:
33 ± 10 years
24-h ECG for HRV (time
domain: SDNN, SDANN,
HRV-triangular index,
rMSSD, PNN50, SNN50)
within 2 weeks of diagnosis
Comparison of
HRV parameters of
leukemia to control
group parameters
Comparison of
HRV parameters of
ALL to HRV
parameters of AML
- SDNN, SDANN, SNN50, PNN50,
HRV-triangular index values
significantly lower in leukemia
patients compared to control
group
- HRV decreases in acute
leukemias
Bettermann
et al., 2001
n = 37
One Group B with BC; mean
age: 56 ± 12 years, females
only Subgroups: B1: with
metastases, B0:
non-metastases
Two groups
Group C: n = 37 healthy
controls; mean age
53 ± 12 years, females only
Group D: n = 40 diabetic
controls; mean age:
55 ± 15 years, females only
24-h ECG for HRV
(frequency domain: LF, HF,
LF/HF, mean RR)
Comparison of
HRV of B, C, D
Comparison of
HRV of B0, B1
- No significant difference of HRV
parameters between B and C
- No significant difference of HRV
parameters between B and D
- Lower HRV in B1 compared to
B0 (non-significant)
HR, heart rate; RR, time interval between R-peaks in the ECG, i.e., the inter-beat interval (IBI); NN, normal-to-normal intervals, i.e., intervals between normal R-peaks;
SDANN, 24-h standard deviation of average NN intervals; SDNN, standard deviation of NN intervals; rMSSD, root mean square of successive differences; pNN50,
percentages of differences between adjacent normal NN intervals > 50 ms; SNN50, R–R intervals exceeding 50 ms; HF, high-frequency power (0.15–0.4 Hz); LF/HF, low-
to high-frequency power ratio; TP, total power; lnHFP, logarithm transformed high-frequency power; VLF, very low frequency (0.0033–0.04 Hz); ET, Ewing Test Score; OS,
overall survival; TTD, time to death; CHD, carcinoid heart disease; WBRT, whole brain radiotherapy; CEA, carcinoembryonic antigen; PSA, prostate-specific antigen; BM,
brain metastasis; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; BC, breast cancer; LC, lung cancer; CRC, colorectal cancer; hnC, head and neck
cancer; PaC, pancreatic cancer; guC, genitourinary cancer; EC, esophagus cancer (also; oesophagus cancer); HCC, hepatocellular carcinoma; GITC, gastrointestinal
cancer; SC, stomach cancer; hbC, hepatobiliary cancer; GC, gastric cancer; PrC, prostate cancer; OC, ovarian cancer; CC, cervical carcinoma; ALL, acute lymphatic
leukemia; AML, acute myeloid leukemia; MRBC, metastatic or recurrent breast cancer; GyC, gynecological cancer; pBT, primary brain tumor.
36; gastrointestinal: 91; and sarcoma: 4. In 704 patients, the type
of cancer was not defined.
In the six retrospective studies (Mouton et al., 2012; De Couck
and Gidron, 2013; De Couck et al., 2013; Couck et al., 2016;
Gidron et al., 2014; Guo et al., 2015), the main outcome measure
was HRV in correlation with survival or tumor marker levels.
Additionally, HRV of groups with and without cancer, and HRV
in patients with and without metastases were compared. Within
the 13 prospective studies, the main outcome measures were HRV
in correlation to overall survival, time to death, 7-day survival
and comparison of HRV within different groups. All studies
reported at least a tendency toward higher HRV signifying a
useful indicator for longer survival. This was true irrespective
of measurement methods, e.g., 24-h electrocardiogram (ECG)
or 10 s ECG, and regardless of HRV indices, e.g., the standard
deviation of normal-to-normal interval (SDNN), high-frequency
(HF) range (0.15–0.4 Hz), heart rate, the root of the mean squared
differences of successive normal-to-normal interval (rMSSD).
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FIGURE 1 | (A) Visualization of the search process leading to the 19 publications selected for the review. (B–G) Kaplan–Meier plots obtained by different studies
investigating the effect of several HRV parameters on the survival probability. (H,I) Dependence on log SDNN on patient characteristics in case of prostate cancer.
(J) Dependence of heart rate complexity in breast cancer patients compared to healthy controls and subjects with diabetes. (K–M) Differences of HRV parameters
comparing healthy controls and cancer patients (K–M) and cancer patients with or without metastasis (L). The subfigures (B–M) were created based on digitally
extracting the numerical data from the published figures in the original published papers. For subfigure (H) and (I) the linear fit with predictions bounds was
recalculated using Matlab (Natick, MA, United States). Statistically significant (p < 0.05) differences in the parameters comparing groups (see J,K–M) are
indicated (∗).
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Our first research question (i) investigated the correlation
between HRV and patients’ prognosis. Giese-Davis et al.
(2015), described a model of overall survival prediction. They
suggested that the correlation between high-frequency power
and overall survival indicates that efferent cardiac vagal activity
may represent overall afferent and efferent information transfer
between the vagal and the immune system and may provide
early clinical prognoses in cancer patients. Guo et al. (2015),
demonstrated with 24-h ECG monitoring a significantly lower
survival rate in patients with SDNN < 70 ms compared to
patients with SDNN > 70 ms. The same conclusion, i.e., lower
SDNN associated with lower survival, was reached in the studies
of Fadul et al. (2010), Kim et al. (2010), Wang et al. (2013), and
also De Couck et al. (2016). Chiang et al. (2013), investigated a
group of patients in a palliative care setting in their last weeks
of life, although a much shorter ECG time frame (10 s to 5 min
ECGs) was applied. This study also showed that patients with
high-frequency power less than two dimensions had a higher risk
of survival of less than 7 days.
The second research question (ii) focused on the correlation
between HRV and tumor burden. Gidron, in Mouton et al.
(2012), De Couck et al. (2013), and Gidron et al. (2014), analyzed
data of PrC, CRC, and NSCLC patients with different cancer
stages and described significantly higher tumor marker levels in
patients with lower HRV.
The third research question (iii) explored the comparison
between different groups of patients and healthy individuals.
Among all studies related to this topic (Bettermann et al., 2001;
Nevruz et al., 2007; Lin and Chen, 2010; De Couck and Gidron,
2013; Gidron et al., 2014; Bijoor et al., 2016; Koszewicz et al.,
2016; Palma et al., 2016), significant differences in the HRV values
were found. HRV was shown to be significantly lower in cancer
patients compared to healthy individuals and also significantly
lower in patients with metastases or generally with advanced
stages III or IV compared to non-metastatic patients. Irrespective
of the HRV measurement duration and variables, all studies
showed a reduced HRV in the groups with more severely affected
disease. Wang et al. (2013) and De Couck et al. (2016) evaluated
the difference of patients with advanced stages compared to
patients with primary and secondary stages as well as compared
to healthy individuals. They reported that disease severity affects
HRV, as patients in early stages showed a significantly higher
vagal nerve activity than patients in later stages.
DISCUSSION
In recent years HRV analysis has attracted increasing interest as
a diagnostic tool in cardiology. In this field, decreased HRV is a
predictor of adverse outcome in myocardial infarction, sudden
cardiac death and congestive heart failure (Kleiger et al., 1987;
Casolo et al., 1989; Cripps et al., 1991; Ponikowski et al., 1997;
La Rovere et al., 1998, 2003; Makikallio et al., 2001). HRV may
also be applied as an early indication for diabetic neuropathy (De
Couck et al., 2012) and is progressively employed by athletes to
assess the level of physical fitness and stress coping ability (De
Meersman, 1993; Chen et al., 2011; Teisala et al., 2014).
For this systematic review, all study designs including
observational studies were considered. According to the GRADE
score, an observational study has an evidence level between low
and moderate. Since most of the publications included here were
observational studies, the overall score of the studies in this
review was between low and moderate. It is important to note
that no strong biases were detected in any of the prospective and
retrospective observational studies included, and that the quality
of all publications was good.
Based on the studies included in this review, HRV may
be a useful non-invasive tool to evaluate prognosis of cancer
patients. However, Fadul et al. (2010), Kim et al. (2010), and
Mouton et al. (2012), still consider it a poor prognosticator,
particularly in patients with advanced cancer. This prognostic
function of HRV, specifically for patients with metastases, has
been discussed in several studies. The main hypothesis is that
a lower HRV is associated with tumor growth through three
pathways, i.e., inflammation, oxidative stress, and sympathetic
nerve activation. De Couck et al. (2013), argued that in earlier
tumor stages, commonly provided treatments such as surgery
and radiotherapy are successful in reducing the tumor burden,
possibly leaving less of a margin for vagal nerve activity to
contribute to the process. By contrast, these treatments may
have less impact in later metastatic stages, where vagal nerve
activity might possibly be of even more importance. HRV-
lowering effects of chemotherapy and radiotherapy appeared to
be reversible with treatment cessation. This effect may therefore
not be relevant for a patient’s prognosis. In a recent study by
Kim et al. (2015), HRV indices were compared to other clinical
variables to capture overall survival in patients with advanced
NSCLC. SDNN significantly correlated with poor survival, but
was not an independent prognosticator for survival. This led to
the conclusion that HRV, as a stand- alone method, might be a
useful tool to monitor the general wellbeing of a patient, rather
than to predict overall survival. Future studies are needed to
clarify these findings.
This systematic review has several limitations. The design
of the six retrospective studies included might be a limiting
factor since HRV may change instantaneously in stressful
situations, meaning that it may be affected by a patient’s state of
mind at the time of measurement. This is particularly relevant
considering the fact that short-term ECGs of seconds to minutes
were often measured in the context of medical consultation, a
potentially stressful situation for the patient depending on the
topic (e.g., diagnosis, progression of disease) addressed. The HRV
measurement may be influenced by stress of the situation thus not
reflecting the patient’s average HRV behavior overall. At the same
time, a high HRV within the context of a medical consultation
may indicate good resilience or coping abilities. Given the
fact that stressful situations – like medical consultations –
may influence HRV measurement, we recommend that HRV
measurements in cancer patients be carried out as 24-h Holter
ECG.
In five of the studies, time domain measurements of HRV,
such as SDNN and rMSSD, were based on 10 s archival ECG
recordings. The authors mentioned the short ECG of 10 s as
a possible limitation but also referred to two studies in which
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HRV obtained from 10 s ECGs was found to be similar to
HRV obtained from 5 and 20 min ECGs (Hamilton et al., 2004;
Nussinovitch et al., 2011). Although both publications suggest
a good correlation of rMSSD derived from a 10 s ECG to the
rMSSD of 5 min ECG, this is not the case for SDNN. In the
publication by Hamilton et al. (2004), SDNN was predictive, but
to a lesser extent than rMSSD. It was concluded that it was unclear
whether SDNN of 10 s ECG should be applied. Nevertheless, the
authors had applied the 10 s ECG variable and defined high and
low HRV with an SDNN above and below 20 ms.
Further studies are needed to clarify the correlation of HRV
with cancer prognosis. It might be that individuals with advanced
coping abilities have better prognosis of cancer. It would be
worth testing whether patients could acquire skills to diminish
acute and long-term stress reactions, supporting their healing
process not only on the physiological but also the psychological
level (Haurand and Aatz, 2015). Options to improve resilience
could include developing the personal coping capabilities of each
patient through HRV biofeedback (Karavidas et al., 2007) or
enhancing vagal activity through vagal stimulating drugs (Bernik
et al., 2002) or vagal nerve stimulators (Murphy and Patil, 2003).
Relaxation exercises have also been found to positively affect HRV
(Asher et al., 2010). In addition, physical exercise and therapeutic
eurhythmy (Seifert et al., 2012) have been shown to exert an
enhancing effect on HRV, which was suggested to be a goal in
cancer treatment due to the association of higher HRV variables
with prolonged survival in cancer patients (Niederer et al., 2013,
2015). Finally, improvement of nutrition has been shown to
positively affect HRV, too (Hansen et al., 2014).
CONCLUSION
This manuscript is the first to systematically compile and appraise
on how HRV is associated with cancer progression and the value
of HRV in predicting cancer patients’ prognosis. The majority of
the studies indicate that a decreased HRV is common in cancer
patients, likely reflecting autonomic dysfunction associated with
the disease. Additionally, the publications reported a correlation
between HRV and the progression and overall survival of
cancer patients. A higher HRV is hereby associated with a
better prognosis for cancer patients. HRV might be a valuable
biomarker in assessing patients’ progression and outcome and
further research on this topic should be conducted.
More severely affected persons exhibit lower HRV, as
demonstrated in this literature search by a comparison of
different patient groups or by the comparison between patients
and healthy individuals. For a healthy individual, a higher level
of HRV is desirable. It indicates a state of calm, relaxation
and capacities to rest and regenerate. There are physical and
psychological illnesses, like heart diseases, diabetes or depression,
where parasympathetic activity including HRV is clearly and
severely reduced (De Couck et al., 2012). Based on the literature,
cancer may be added to the list of illnesses where HRV is reduced.
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